LEXICON PHARMACEUTICALS, INC.LXRXEarnings & Financial Report
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 1...
LXRX Q3 2025 Key Financial Metrics
营收
$14.2M
毛利润
$14.2M
营业利润
$-12.2M
净利润
$-12.8M
毛利率
99.9%
营业利润率
-85.9%
净利率
-90.0%
同比增长
714.6%
EPS
$-0.04
资金流向
LEXICON PHARMACEUTICALS, INC. Q3 2025 Financial Summary
LEXICON PHARMACEUTICALS, INC. reported revenue of $14.2M for Q3 2025, with a net profit of $-12.8M (-90.0% margin). Cost of goods sold was $10.0K, operating expenses totaled $26.4M.
Key Financial Metrics
| Total Revenue | $14.2M |
|---|---|
| Net Profit | $-12.8M |
| Gross Margin | 99.9% |
| Operating Margin | -85.9% |
| Report Period | Q3 2025 |
LEXICON PHARMACEUTICALS, INC. Annual Revenue by Year
LEXICON PHARMACEUTICALS, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $6.0M).
| Year | Annual Revenue |
|---|---|
| 2024 | $6.0M |
| 2023 | $1.1M |
利润表
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $671000 | $1.1M | $1.6M | $1.7M | $1.6M | $1.3M | $28.9M | $14.2M |
| 同比增长 | N/A | N/A | 455.7% | 1076.4% | 131.0% | 15.5% | 1685.2% | 714.6% |
资产负债表
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $229.4M | $417.2M | $373.4M | $321.1M | $298.4M | $297.7M | $225.6M | $205.9M |
| 总负债 | $136.3M | $128.4M | $133.4M | $142.6M | $152.5M | $174.6M | $96.1M | $85.8M |
| 股东权益 | $93.1M | $288.9M | $240.0M | $178.5M | $145.9M | $123.0M | $129.4M | $120.2M |
现金流量表
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $-50.5M | $-55.1M | $-48.5M | $-53.6M | $-21.5M | $-43.8M | $17.0M | $-23.8M |
